Nymox Pharmaceutical (NYMX) vs. IPSEN S A/S (IPSEY) Financial Analysis

Nymox Pharmaceutical (NASDAQ:NYMX) and IPSEN S A/S (OTCMKTS:IPSEY) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Nymox Pharmaceutical and IPSEN S A/S, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nymox Pharmaceutical 0 0 0 0 N/A
IPSEN S A/S 2 0 0 0 1.00

Valuation & Earnings

This table compares Nymox Pharmaceutical and IPSEN S A/S’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Nymox Pharmaceutical $220,000.00 504.49 -$13.42 million N/A N/A
IPSEN S A/S $2.27 billion 5.36 $307.78 million $0.93 39.11

IPSEN S A/S has higher revenue and earnings than Nymox Pharmaceutical.

Insider & Institutional Ownership

7.3% of Nymox Pharmaceutical shares are held by institutional investors. 54.0% of Nymox Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Dividends

IPSEN S A/S pays an annual dividend of $0.22 per share and has a dividend yield of 0.6%. Nymox Pharmaceutical does not pay a dividend. IPSEN S A/S pays out 23.7% of its earnings in the form of a dividend.

Risk & Volatility

Nymox Pharmaceutical has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500. Comparatively, IPSEN S A/S has a beta of 0.22, meaning that its stock price is 78% less volatile than the S&P 500.

Profitability

This table compares Nymox Pharmaceutical and IPSEN S A/S’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Nymox Pharmaceutical -3,455.58% -4,095.76% -585.27%
IPSEN S A/S N/A N/A N/A

Summary

IPSEN S A/S beats Nymox Pharmaceutical on 6 of the 11 factors compared between the two stocks.

Nymox Pharmaceutical Company Profile

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease. Its lead drug candidate is Fexapotide Triflutate (NX-1207) that has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia; and is in Phase II clinical trial for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company markets its products in Canada, the United States, Europe, and internationally. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, Bahamas.

IPSEN S A/S Company Profile

Ipsen S.A. operates as a pharmaceutical company worldwide. It operates in two segments, Specialty Care and Consumer Healthcare. The company offers drugs in oncology, endocrinology, neurology, gastroenterology, cognitive disorders, and rheumatology areas. Its products include Somatuline, which is an injectable treatment for acromegaly and neuroendocrine tumors; Cabometyx, a tablet formulation of cabozantinib for renal cell carcinoma; Onivyde for metastatic pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, and female sterility; and Dysport for motor disorders and muscular spasticity. The company also provides NutropinAq, a liquid formulation, for treating growth failure in children due to growth hormone deficiency in adults; and Increlex used for long-term treatment of growth failure in children and adolescents. In addition, it offers Smecta, a formulation for use in the treatment of chronic and acute diarrhea; Forlax, an osmotic laxative indicated for the symptomatic treatment of constipation in adults and children; Fortrans for the treatment of intestinal cleaning; Eziclen, an osmotic laxative indicated for the cleaning of bowel; Etiasa for the treatment of inflammatory bowel diseases; and Tanaka for mild cognitive impairment related to age, pathophysiological deficiencies, vertigo, retinal deficits, acute or chronic hearing impairment, and tinnitus. Further, the company provides Adenuric for the treatment of gout; Prontalgine, an analgesic for the treatment of moderate to severe pain; Buscopan, an antispasmodic; Suppositoria Glycerini, a laxative; and Mucothiol and Mucodyne, which are expectorants for cough and flu. Ipsen S.A. has a strategic agreement with Arix Bioscience plc to develop and commercialize various therapies. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.

Receive News & Ratings for Nymox Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply